Wockhardt, a prominent pharmaceutical and biotechnology company based in India, experienced a significant turnaround in its financial performance for the quarter ended March 2026. The company reported a net profit of ₹164 crore for Q4FY26, a notable recovery from a net loss of ₹45 crore in the same quarter last year. This improvement was driven by strong revenue growth, which reached ₹965 crore, bolstered by a 124% increase in the emerging markets segment and a 126% growth in its overall biotech operations. As a result, Wockhardt's shares surged 12.55% to a nine-month high of ₹1,604 per share. For the full fiscal year 2026, the company achieved a total revenue of ₹3,373 crore, reflecting an 11% increase from the previous year, alongside a 51% rise in EBITDA to ₹630 crore. Looking ahead, Wockhardt aims to capitalize on the global diabetes market with planned launches of insulin analogues and anticipates continued double-digit growth in its India biotech operations.